Assessment of the total direct medical cost of patients in secondline TNF inhibitor therapy and of the respect of clinical practice recommendations

(PDF, 61.3 ko)

Until recently, in the absence of a specific marketing authorisation, patients who failed a TNFa inhibitor (anti-TNFa) therapy switched to another TNF a inhibitor. No specific study has been conducted on this specific population treated in 2nd and subsequent lines, so that resources consumption of this population was unknown. In order to feed a budget impact model (EULAR 2007 - Poster SAT0024) an observational study has been developed.

Objective

To establish the total direct medical cost of patients in second-line anti-TNFa therapy from the French health care system perspective and to assess whether the three treatments marketed in France - infliximab (INF), etanercept (ETA) and adalimumab (ADA) - are administered with respect to the clinical practice recommendations.